Suppr超能文献

Mdm2和Mdm4单倍剂量不足在肿瘤发生和发展中的作用

Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development.

作者信息

Terzian Tamara, Wang Yongxing, Van Pelt Carolyn S, Box Neil F, Travis Elisabeth L, Lozano Guillermina

机构信息

Department of Cancer Genetics, Box 1010, The University of Texas M. D. Anderson Cancer Center, Baylor College of Medicine, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

出版信息

Mol Cell Biol. 2007 Aug;27(15):5479-85. doi: 10.1128/MCB.00555-06. Epub 2007 May 25.

Abstract

The tumor suppressor p53 is inactivated by multiple mechanisms that include mutations of the p53 gene itself and increased levels of the p53 inhibitors MDM2 and MDM4. Mice lacking Mdm2 or Mdm4 exhibit embryo-lethal phenotypes that are completely rescued by concomitant deletion of p53. Here we show that Mdm2 and Mdm4 haploinsufficiency leads to increased p53 activity, exhibited as increased sensitivity to DNA damage and decreased transformation potential. Moreover, in in vivo tumor development, Emu-myc Mdm4+/- mice show a delayed onset of B-cell lymphomas compared to Emu-myc mice. Additionally, Mdm2+/- Mdm4+/- double-heterozygous mice are not viable and exhibit defects in hematopoiesis and cerebellar development. The defects in Mdm2+/- Mdm4+/- mice are corrected by deletion of a single p53 allele. These findings highlight the exquisite sensitivity of p53 to Mdm2 and Mdm4 levels and suggest that some cell types may be more sensitive to therapeutic drugs that inhibit the Mdm-p53 interaction.

摘要

肿瘤抑制因子p53可通过多种机制失活,这些机制包括p53基因本身的突变以及p53抑制剂MDM2和MDM4水平的升高。缺乏Mdm2或Mdm4的小鼠表现出胚胎致死表型,而同时缺失p53可完全挽救该表型。在此我们表明,Mdm2和Mdm4单倍体不足会导致p53活性增加,表现为对DNA损伤的敏感性增加和转化潜能降低。此外,在体内肿瘤发生过程中,与Emu-myc小鼠相比,Emu-myc Mdm4+/-小鼠的B细胞淋巴瘤发病延迟。另外,Mdm2+/- Mdm4+/-双杂合小鼠无法存活,并在造血和小脑发育方面表现出缺陷。通过缺失单个p53等位基因可纠正Mdm2+/- Mdm4+/-小鼠的缺陷。这些发现突出了p53对MDM2和MDM4水平的高度敏感性,并表明某些细胞类型可能对抑制Mdm-p53相互作用的治疗药物更为敏感。

相似文献

1
Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development.
Mol Cell Biol. 2007 Aug;27(15):5479-85. doi: 10.1128/MCB.00555-06. Epub 2007 May 25.
2
Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development.
Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3226-31. doi: 10.1073/pnas.0508500103. Epub 2006 Feb 21.
3
Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4.
Mol Cell Biol. 2006 Jan;26(1):192-8. doi: 10.1128/MCB.26.1.192-198.2006.
4
Mouse models of Mdm2 and Mdm4 and their clinical implications.
Chin J Cancer. 2013 Jul;32(7):371-5. doi: 10.5732/cjc.012.10286. Epub 2013 Jan 18.
5
Widespread overexpression of epitope-tagged Mdm4 does not accelerate tumor formation in vivo.
Mol Cell Biol. 2010 Nov;30(22):5394-405. doi: 10.1128/MCB.00330-10. Epub 2010 Sep 20.
8
Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo.
Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3232-7. doi: 10.1073/pnas.0508476103. Epub 2006 Feb 21.
10
The MDM4/MDM2-p53-IGF1 axis controls axonal regeneration, sprouting and functional recovery after CNS injury.
Brain. 2015 Jul;138(Pt 7):1843-62. doi: 10.1093/brain/awv125. Epub 2015 May 16.

引用本文的文献

2
PPIL2 is a target of the JAK2/STAT5 pathway and promotes myeloproliferation via degradation of p53.
J Clin Invest. 2025 May 8;135(13). doi: 10.1172/JCI181394. eCollection 2025 Jul 1.
3
ZNF768 loss amplifies p53 action and reduces lung tumorigenesis in mice.
Oncogene. 2025 Mar 25. doi: 10.1038/s41388-025-03352-w.
4
Endogenous p53 inhibitor TIRR dissociates systemic metabolic health from oncogenic activity.
Cell Rep. 2024 Jun 25;43(6):114337. doi: 10.1016/j.celrep.2024.114337. Epub 2024 Jun 9.
5
p53 in the Molecular Circuitry of Bone Marrow Failure Syndromes.
Int J Mol Sci. 2023 Oct 6;24(19):14940. doi: 10.3390/ijms241914940.
8
Tissue specificity and spatio-temporal dynamics of the p53 transcriptional program.
Cell Death Differ. 2023 Apr;30(4):897-905. doi: 10.1038/s41418-023-01123-2. Epub 2023 Feb 8.
9
Lessons from Using Genetically Engineered Mouse Models of MYC-Induced Lymphoma.
Cells. 2022 Dec 22;12(1):37. doi: 10.3390/cells12010037.
10
Role of p53 in Regulating Radiation Responses.
Life (Basel). 2022 Jul 21;12(7):1099. doi: 10.3390/life12071099.

本文引用的文献

1
Tumor suppression and normal aging in mice with constitutively high p53 activity.
Genes Dev. 2006 Jan 1;20(1):16-21. doi: 10.1101/gad.1378506.
2
Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4.
Mol Cell Biol. 2006 Jan;26(1):192-8. doi: 10.1128/MCB.26.1.192-198.2006.
5
COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas.
Cancer Res. 2004 Oct 15;64(20):7226-30. doi: 10.1158/0008-5472.CAN-04-2601.
6
Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity.
Mol Cell Biol. 2004 Jul;24(13):5835-43. doi: 10.1128/MCB.24.13.5835-5843.2004.
8
Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation.
Cell. 2003 Mar 21;112(6):779-91. doi: 10.1016/s0092-8674(03)00193-4.
9
Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis.
EMBO J. 2003 Mar 17;22(6):1442-50. doi: 10.1093/emboj/cdg133.
10
mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation.
Mol Cell Biol. 2003 Jan;23(2):462-72. doi: 10.1128/MCB.23.2.462-473.2003.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验